Switch theme
Sign up to access all valuation multiples
Kenvue is the world’s largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power.
2022
22K+
LTM Revenue $15.5B
LTM EBITDA $3.7B
$53.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kenvue has a last 12-month revenue (LTM) of $15.5B and a last 12-month EBITDA of $3.7B.
In the most recent fiscal year, Kenvue achieved revenue of $15.5B and an EBITDA of $2.5B.
Kenvue expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kenvue valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $15.5B | XXX | $15.5B | XXX | XXX | XXX |
| Gross Profit | $9.3B | XXX | $9.0B | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $3.7B | XXX | $2.5B | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 16% | XXX | XXX | XXX |
| EBIT | $3.3B | XXX | $2.6B | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $2.2B | XXX | $1.0B | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $7.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kenvue's stock price is $24.
Kenvue has current market cap of $45.8B, and EV of $53.6B.
See Kenvue trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $53.6B | $45.8B | XXX | XXX | XXX | XXX | $1.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kenvue has market cap of $45.8B and EV of $53.6B.
Kenvue's trades at 3.5x EV/Revenue multiple, and 21.7x EV/EBITDA.
Equity research analysts estimate Kenvue's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kenvue has a P/E ratio of 20.9x.
See valuation multiples for Kenvue and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $45.8B | XXX | $45.8B | XXX | XXX | XXX |
| EV (current) | $53.6B | XXX | $53.6B | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | 14.7x | XXX | 21.7x | XXX | XXX | XXX |
| EV/EBIT | 16.1x | XXX | 20.4x | XXX | XXX | XXX |
| EV/Gross Profit | 5.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.9x | XXX | 44.5x | XXX | XXX | XXX |
| EV/FCF | 34.5x | XXX | 40.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKenvue's last 12 month revenue growth is 2%
Kenvue's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.
Kenvue's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kenvue's rule of X is 29% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kenvue and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 23% | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kenvue acquired XXX companies to date.
Last acquisition by Kenvue was XXXXXXXX, XXXXX XXXXX XXXXXX . Kenvue acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kenvue founded? | Kenvue was founded in 2022. |
| Where is Kenvue headquartered? | Kenvue is headquartered in United States of America. |
| How many employees does Kenvue have? | As of today, Kenvue has 22K+ employees. |
| Who is the CEO of Kenvue? | Kenvue's CEO is Mr. Thibaut Mongon. |
| Is Kenvue publicy listed? | Yes, Kenvue is a public company listed on NYS. |
| What is the stock symbol of Kenvue? | Kenvue trades under KVUE ticker. |
| When did Kenvue go public? | Kenvue went public in 2023. |
| Who are competitors of Kenvue? | Similar companies to Kenvue include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
| What is the current market cap of Kenvue? | Kenvue's current market cap is $45.8B |
| What is the current revenue of Kenvue? | Kenvue's last 12 months revenue is $15.5B. |
| What is the current revenue growth of Kenvue? | Kenvue revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Kenvue? | Current revenue multiple of Kenvue is 3.5x. |
| Is Kenvue profitable? | Yes, Kenvue is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kenvue? | Kenvue's last 12 months EBITDA is $3.7B. |
| What is Kenvue's EBITDA margin? | Kenvue's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Kenvue? | Current EBITDA multiple of Kenvue is 14.7x. |
| What is the current FCF of Kenvue? | Kenvue's last 12 months FCF is $1.6B. |
| What is Kenvue's FCF margin? | Kenvue's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Kenvue? | Current FCF multiple of Kenvue is 34.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
